Evidence

Evidence-based software as medicine

We research continuously, to keep improving a therapy built on the guidelines.

What we measure today

1,500+

patients supported¹

84%

still using Noctua Care after one month²

93%

would recommend the program³

4.7

average rating on Google Play⁴

Our therapies build on the accepted guidelines for lowering risk through behavioral and lifestyle therapy.

European Society of Cardiology
The modules follow ESC guidance on secondary prevention: treatment, physical activity, diet, mental health. Every goal the program sets corresponds to a target those guidelines name.
Clinical review throughout
Every module is built with physicians and nursing staff, and reviewed by a cardiologist before it ships.

What we are working on, and how far along it is.

Completed
Content audit
Every module in the program reviewed by CHU Bordeaux.
Completed
Behavioral science engine
Built with the EVIDANS team at CHU Bordeaux.
Completed
DiSuACS engagement trial
Evaluation of the Feasibility of a Digital Support for Patients after Acute Coronary Syndrome. 32 patients over 30 days. Endpoints: usability and engagement.
Q3 2026
Quantitative analysis
Behavior change actually implemented after the pilot trial.
Q1 2027
Exploratory randomized trial
200 patients at CHU de Bordeaux and CH de Pau, evaluating the medical impact of the behavior change program.

Noctua Care can target any cardiometabolic disease, symptom or side effect with an underlying neurological or behavioral component.

Patients supported: internal data, August 2026.
Use at one month: DiSuACS, single-arm feasibility study, CHU Bordeaux, 2026. n=32, observed over 30 days. An engagement measure, not an efficacy result.
Recommendation: patient survey, 2026. Sample size and field dates still need recording.
Google Play rating: read from the app listing, August 2026.